Press Release May 23, 2018

Celyad Closes $54.4 Million Global Offering

The Life Sciences team advised Celyad on the closing of its global offering of 2,070,000 ordinary shares to purchasers in the United States, Europe and certain countries outside the United States and Europe, comprised of 568,500 ordinary shares in the form of American Depositary Shares (ADSs) at a price per ADS of $26.28, and 1,501,500 ordinary shares at a price per share of €22.29. The number of ADSs and ordinary shares sold in the global offering reflects the full exercise of the underwriters’ option to purchase additional shares.

The gross proceeds to Celyad from the global offering amounted to approximately $54.4 million (approximately €46.1 million), before deducting underwriting commissions and estimated offering expenses.

Based in Mont-Saint-Guibert, Belgium and Boston, Massachusetts, Celyad is a clinical-stage biopharmaceutical company focused on the development of specialized CAR-T cell-based therapies to treat a broad range of solid and hematologic tumors.

The Goodwin team was led by partner Michael Bison and included associates Stephanie Richards, Andre Garron, Riley Lovendale, Kristin Eberhart and Stephen Fox.

For additional details on the offering, please read the press release.